7 Hills Pharma: FDA Fast Track Designation for 7HP349

7 Hills Pharma: FDA Fast Track Designation for 7HP349

7 Hills Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead clinical-stage immunostimulant 7HP349, combined with a CTLA-4 inhibitor, to treat unresectable or metastatic malignant melanoma if...